Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Non-Hodgkin lymphoma, adult
Stage/Subtype:  indolent, recurrent adult non-Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 250 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 113676, NCI-2012-01195, NCT01200589
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Double Cord Versus Haploidentical (BMT CTN 1101)
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 715, NCT01597778
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-313-0124, NCI-2013-01738, NCT01732913
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Age: 65 and under
Trial IDs: CB-AB006, NCI-2013-00758, 2012-0166, NCT01854567
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-007, NCI-2014-02022, NCT01938001
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-008, NCI-2015-00708, NCT01996865
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-07, NCI-2014-00977, NCT02004522
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: E1912, NCI-2014-00118, ECOG-E1912, NCT02048813
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-12, NCI-2014-02041, NCT02049515
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 1409.00, NCI-2010-00130, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Pyrimethamine in Treating Patients with Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-421, NCI-2010-01303, NCT01066663
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TED10893, NCI-2010-02332, U1111-1116-5472, NCT01084252
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide after Donor Bone Marrow Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 6 months to 85
Trial IDs: J1151, NCI-2014-01339, CR00000875, NA_00048378, NA_00048378 / CIR00006178, NCI-2014-00310, NCT01342289
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 201112026, NCI-2014-01309, NCI-2011-02328, POL-4, NCT01413568
Lamivudine and Tenofovir in Treating a Viral Infection in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UMCC 2010.097, NCI-2012-00387, HUM00033361, HUM 33361, NCT01528865
Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With High-Risk Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 11411, NCI-2012-00747, NCT01575860
Start Over